Skip to main content Accesibility Help
×
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 3
  • Cited by
    This chapter has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Seddon, Jennifer L. Birchwood, Max Copello, Alex Everard, Linda Jones, Peter B. Fowler, David Amos, Tim Freemantle, Nick Sharma, Vimal Marshall, Max and Singh, Swaran P. 2016. Cannabis Use Is Associated With Increased Psychotic Symptoms and Poorer Psychosocial Functioning in First-Episode Psychosis: A Report From the UK National EDEN Study. Schizophrenia Bulletin, Vol. 42, Issue. 3, p. 619.

    CASTLE, DAVID 2008. Letter to the Editor: Drawing conclusions about cannabis and psychosis. Psychological Medicine, Vol. 38, Issue. 03,

    Hinton, Mark Edwards, Jane Elkins, Kathryn Harrigan, Susy M. Donovan, Kerri Purcell, Rosemary and McGorry, Patrick D. 2007. Reductions in cannabis and other illicit substance use between treatment entry and early recovery in patients with first-episode psychosis. Early Intervention in Psychiatry, Vol. 1, Issue. 3, p. 259.

    ×
  • Print publication year: 2004
  • Online publication date: December 2009

8 - Cannabis abuse and the course of schizophrenia

Summary

As detailed elsewhere in this book (Chapter 3), cannabis has been used for centuries to produce euphoria and relaxation as desired mental effects. However, adverse effects of intoxication with cannabis include anxiety and panic (Thomas, 1996; Reilly et al., 1998), depression (Bovasso, 2001; Patton et al., 2002: see Chapter 4), and impairment in certain domains of cognitive function (see Chapters 3 and 13). Psychosis, including paranoid delusions and hallucinations, has been found to be an effect of cannabis use in cohort studies from New Zealand (Thomas, 1996), Vietnam (Talbott and Teague, 1969), India (Chopra and Smith, 1974) and Pakistan (Chaudry et al., 1991) (Chapter 6). This work suggests that cannabis, especially in high doses, can produce a toxic psychosis in people without mental disorders. Evidence for cannabis (and especially heavy abuse) as a causal risk factor for psychotic disorders comes from epidemiological studies of Swedish conscripts (Andreasson et al., 1987; Zammit et al., 2002), from the Dunedin study from New Zealand (Arsenault et al., 2002), from a Dutch sample (Van Os et al., 2002) and from a study of Israeli conscripts (Weiser et al., 2001) (see Chapter 7).

Schizophrenia and related psychotic disorders are clinical syndromes with a wide variation in symptoms between individuals (Thaker and Carpenter, 2001). Factor-analytic studies of schizophrenia have revealed that the symptoms are best described by three dimensions or syndromes: reality distortion (hallucinations and delusions), psychomotor poverty (restriction of affect, loss of motivation and restricted emotional experience) and disorganization (disorganized thought, incongruity of affect and bizarre behaviour) (Liddle, 1987).

Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Marijuana and Madness
  • Online ISBN: 9780511543630
  • Book DOI: https://doi.org/10.1017/CBO9780511543630
Please enter your name
Please enter a valid email address
Who would you like to send this to *
×
REFERENCES
American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R), 3rd edn. Washington, DC: American Psychiatric Association
Andreasson, S., Allebeck, P., Engström, A. and Rydberg, U. (1987). Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet, 2, 1483–1486
Arseneault, L., Cannon, M., Poulton, R.et al. (2002). Cannabis use in adolescence and risk for adult psychosis; longitudinal prospective study. Br. Med. J., 325, 1212–1213
Bersani, G., Orlandi, V., Kotzalidis, G. D. and Pancheri, P. (2002). Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur. Arch. Psychiatry Clin. Neurosci., 252, 86–92
Bilder, R. M., Goldman, R. S., Robinson, D.et al. (2000). Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry, 157, 549–559
Bovasso, G. B. (2001). Cannabis abuse as a risk factor for depressive symptoms. Am. J. Psychiatry, 158, 2033–2037
Bühler, B., Hambrecht, M., Löffler, W., Heiden an, W. and Häfner, H. (2002). Precipitation and determination of the onset and course of schizophrenia by substance abuse – a retrospective and prospective study of 232 population-based first illness episodes. Schizophr. Res., 54, 243–251
Caspari, D. (1999). Cannabis and schizophrenia: results of a follow-up study. Eur. Arch. Psychiatry Clin. Neurosci., 249, 45–49
Chaudry, H. R., Moss, H. B., Bashir, A.et al. (1991). Cannabis psychosis following bhang ingestion. Br. J. Addict., 86, 1075–1081
Chopra, G. S. and Smith, J. W. (1974). Psychotic reactions following cannabis use in East Indians. Arch. Gen. Psychiatry, 30, 24–27
Cleghorn, J. M., Kaplan, R. D., Szechtman, B.et al. (1991). Cannabis abuse and schizophrenia: effect on symptoms but not on neurocognitive function. J. Clin. Psychiatry, 52, 26–30
Dixon, L., Haas, G., Weiden, P. J., Sweeney, J. and Frances, A. J. (1991). Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am. J. Psychiatry, 148, 224–230
Gupta, S., Hendricks, S., Kenkel, A. M., Bhatia, S. C. and Haffke, E. A. (1996). Relapse in schizophrenia: is there a relationship to substance abuse?Schizophr. Res., 20, 153–156
Hunt, G. E., Bergen, J. and Bashir, M. (2002). Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr. Res., 54, 253–264
Knudsen, P. and Vilmar, T. (1984). Cannabis and neuroleptic agents in schizophrenia. Acta Psychiatr. Scand., 69, 162–174
Kovasznay, B., Fleischer, J., Tanenberg-Karant, M.et al. (1997). Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr. Bull., 23, 195–201
Liddle, P. (1987). The symptoms of chronic schizophrenia. A re-examination of the positive–negative dichotomy. Br. J. Psychiatry, 151, 145–151
Linszen, D. H., Dingemans, P. M. and Lenior, M. E. (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch. Gen. Psychiatry, 51, 273–279
Linszen, D. H., Dingemans, P. M. and Lenior, M. E. (1995). Symptom dimensions of schizophrenic and cannabis abuse: a longitudinal study. Schizophr. Res., 15, 16
Martin, G. W., Wilkinson, A. and Kapur, B. M. (1988). Validation of self-reported cannabis use by urine analysis. Addict. Behav., 13, 147–150
Martinez-Arevalo, M. J., Calcedo-Ordoñez, A. and Varo-Prieto, J. R. (1994). Cannabis consumption as prognostic factor in schizophrenia. Br. J. Psychiatry, 164, 679–684
Negrete, J. C., Knapp, W. P., Douglas, D. E. and Smith, B. (1986). Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychol. Med., 16, 515–520
Patton, G. C., Coffey, C., Carlin, J. B.et al. (2002). Cannabis use and mental health in young people: cohort study. Br. Med. J., 325, 1195–1198
Peralta, V. and Cuesta, M. J. (1992). Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr. Scand., 85, 127–130
Reilly, D., Didcott, R., Swift, W.et al. (1998). Longterm cannabis use: characteristics of users in Australian rural areas. Addiction, 93, 837–846
Talbott, J. A. and Teague, J. W. (1969). Marijuana psychosis. J.A.M.A., 210, 299–302
Thaker, G. K. and Carpenter, W. T. (2001). Advances in schizophrenia. Nature Med., 7, 667–671
Thomas, H. (1996). A community survey of adverse effects of cannabis use. Drug Alcohol Depend., 42, 201–207
Treffert, D. A. (1978). Marijuana use in schizophrenia: a clear hazard. Am. J. Psychiatry, 135, 1213–1215
Does., A. J. W., Dingemans, P. M. A. J., Linszen, D. H., Nugter, M. A. and Scholte, W. F. (1995). Dimensions and subtypes of recent-onset schizophrenia: a longitudinal analysis. J. Nerv. Ment. Dis., 183, 681–687
Os, J., Bak, M.et al. (2002). Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol., 156, 4, 319–327
Weil, A. T. (1970). Adverse reactions to marijuana, classification and suggested treatment. N. Engl. J. Med., 282, 997–1000
Weiser, M., Weisenberg, A., Rabinowitz, J.et al. (2001). Association between nonpsychotic psychiatric diagnosis in adolescent males and subsequent onset of schizophrenia. Arch. Gen. Psychiatry, 58, 959–964
Zammit, S., Allebeck, P., Andreasson, S., Lundberg, I. and Lewis, G. (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. Br. Med. J., 325, 1199–1201
Zisook, S., Heaton, R., Moranville, J.et al. (1992). Past substance abuse and clincal course of schizophrenia. Am. J. Psychiatry, 149, 552–553